One of the greatest discoveries in medicine was the observation by Dr. Alexander Fleming that the fungus, Penicillium notatum, excreted a substance, subsequently named penicillin, that inhibited growth of bacteria. This discovery was particularly fortuitous because of penicillin's low toxicity to human cells. Penicillin is an exemplary antibiotic because its primary mechanism of action is to interfere with or inhibit the synthesis of the bacterial cell wall. In addition, the physician often feels that the antibiotic is innocuous and cannot cause harm to the patient. Another instance when antibiotics are prescribed indiscriminately is in postoperative fever. The typical response to a patient who has had a hysterectomy or cesarean section and develops a fever is to give antibiotics without a thorough evaluation. When the patient responds, e.g., becomes afebrile in 24 hours, the physician feels justified in having administered antibiotics.
Antibiotics are not tocolytic agents. However, it is common practice to administer antibiotics to pregnant women in preterm labor in the belief that antibiotics can increase the latent phase and therefore allow the administration of steroids. There must also be sufficient safety data. The societies must be emphatic that if there are no data to support use of a particular drug in pregnant women it should be withheld from these individuals as well as from breastfeeding women.
The infectious disease societies should also assist the pharmaceutical industry in the development of these agents and not be influenced by the opportunity to gain financial support for their research The pharmaceutical industry has been a friend to medicine, supporting research and education. The societies must, in turn, be a true friend to the pharmaceutical industry by being honest and helping to guide them through product development.
Although profit is a motivator, short-term profit can turn out to be long-term loss if unexpected adversity results from the administration of an antimicrobial agent. The academic investigator, whether or not performing clinical or basic science research supported by the pharmaceutical industry, must remain neutral with regard to the industry. The investigator must also remain distanced from the industry and, thereby, unencumbered in rendering data, opinions, and recommendations.
Infectious diseases remain a serious threat to the well-being of our patients. The members of IDSOG and IIDSOG-USA have a responsibility to our patients to bring forth not only new and better antimicrobials, but also agents that truly are an improvement over existing ones. The societies should also help to ensure that these agents are safe. Although our role in preventing selection of resistant bacteria, fungi, and parasites may seem minor, it is a significant one.
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